Results in Figure 6 showed that even though treatment with FAK inhibitor TAE226 alone did not significantly inhibit leukemia growth in mice by body bioluminescence [mean (SD) radiance vs. control, 3386 (2294) vs. 4979 (4609) × 106 p/s/cm2/sr, p = 0.38 on day 44], the FAK inhibitor TAE226 in combination with TKI nilotinib provided the most optimum growth inhibition 4–6 weeks post inoculation. This evidence concerns the gene PTK2 and leukemia.